5-(piperidin-1-ylmethyl)-1H-indole | 1268340-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-(piperidin-1-ylmethyl)-1H-indole
• CAS: 1268340-89-1
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: KMFNVBXRAMSHBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1H-indol-5-yl)(piperidin-1-yl)methanethione 在 五羰基溴化锰(I) 、 氢气 、 三乙胺 、 copper(I) bromide 作用下， 100.0 ℃ 、3.0 MPa 条件下， 以61 %的产率得到5-(piperidin-1-ylmethyl)-1H-indole
  参考文献：
  名称：

  硫代酰胺的锰催化加氢脱硫

  摘要：

  开发了硫代酰胺的第一个锰催化氢化脱硫，以选择性地裂解 C=S 键。值得注意的是，在这种基于锰的方案中，醛、酮、砜甚至硝基等官能团可以得到前所未有的耐受性，尽管它们对还原条件很敏感。

  DOI：

  10.1002/anie.202215963

文献信息

• Cross-Coupling of Mesylated Phenol Derivatives with Potassium Ammonio- and Amidomethyltrifluoroborates
  作者：Gary A. Molander、Floriane Beaumard

  DOI：10.1021/ol200128y

  日期：2011.3.4

  A large array of aryl and heteroaryl mesylates have been successfully employed as electrophiles in a Csp(2)-Csp(3) Suzuki-Miyaura cross-coupling with potassium ammonio- and amidomethyltrifluoroborates to afford the corresponding products in high yields.
• [EN] OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND<br/>[FR] FORMULATION OPHTALMOLOGIQUE DE COMPOSÉ D'INHIBITEUR DE LA KINASE RHO
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2009155209A1

  公开（公告）日：2009-12-23

  The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at a pH between 6.3 to 7.8, wherein the ROCK inhibitor, the surfactant, and the tonicity agent are compatible in the formulation. The aqueous ophthalmic formulations of this invention have an increased ocular bioavailability and/or aqueous humor concentrations without a concomitant increase in systemic concentrations. The present invention further provides a method of reducing intraocular pressure, particularly a method of treating glaucoma, by administering the aqueous pharmaceutical formulation to a subject.
• [EN] METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS<br/>[FR] PROCÉDÉ PERMETTANT DE TRAITER DES MALADIES PULMONAIRES PAR DES COMPOSÉS INHIBITEURS DE RHO KINASE
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2009158587A1

  公开（公告）日：2009-12-30

  This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.
• [EN] METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS<br/>[FR] PROCÉDÉ POUR TRAITER DES MALADIES PULMONAIRES EN UTILISANT DES COMPOSÉS INHIBITEURS DE KINASE RHO
  申请人：INSPIRE PHARMACEUTICALS INC

  公开号：WO2010065782A1

  公开（公告）日：2010-06-10

  This invention relates to methods of treating pulmonary diseases in patients that beta adrenergic receptor agonist therapy is not effective. The method comprises the steps of: identifying a patient who suffers from a pulmonary disease and has reduced responsiveness to treatment with one or more beta adrenergic receptor agonists, and administering to the patient an effective amount of a Rho kinase inhibitor compound, wherein said pulmonary disease is selected from the group consisting of: asthma, chronic obstructive pulmonary disease, respiratory tract illness caused by respiratory syncytial virus infection such as RSV-induced wheezing, airway hyperreactivity, or bronchiolitis, bronchiectasis, alpha-1-antitrypsin deficiency, lymphangioleiomyomatosis, cystic fibrosis, bronchiolitis or wheezing caused by agents other than respiratory syncytial virus, chronic bronchitis, and occupational lung diseases.
• Manganese‐Catalyzed Hydrogenative Desulfurization of Thioamides
  作者：Zelong Wang、Silin Chen、Chao Chen、Yunhui Yang、Congyang Wang

  DOI：10.1002/anie.202215963

  日期：2023.2

  The first manganese-catalyzed hydrogenative desulfurization of thioamides was developed to selectively cleave the C=S bond. Remarkably, functional groups such as aldehyde, ketone, sulfone, or even nitro could be unprecedentedly tolerated in this manganese-based protocol and this, despite their sensitivity to reductive conditions.

  开发了硫代酰胺的第一个锰催化氢化脱硫，以选择性地裂解 C=S 键。值得注意的是，在这种基于锰的方案中，醛、酮、砜甚至硝基等官能团可以得到前所未有的耐受性，尽管它们对还原条件很敏感。